anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Production of DNA vectors with the inserted gene of a target protein and the production of recombinant protein in eukaryotic cell cultures is disclosed. A composition for the intensive production of target protein in eukaryotic cells comprises a DNA vector with the inserted gene of a target protein and an agonist of cell receptors belonging to the pattern recognition receptor (PRR) family selected from the following agonists: TLR2, or TLR4, or TLR5, or TLR7, or TLR8, or TLR9, or NOD1 receptor, or NOD2 receptor, used in an optimal ratio. TLR2 is a lipoteichoic acid. TLR2 is a lipopeptide. TLR4 can be either bacterial lipopolysaccharide or acidic peptidoglycan (APG) having a molecular weight of 1200-40000 kDa. TLR5 is flagellin TLR7 is either imiquimod or CL097, an imidazoquinoline derivative. TLR8 is either imiquimod or CL097, an imidazoquinoline derivative. TLR9 is either oligonucleotide CpG ODN 1826 or oligonucleotide CpG ODN 2006.
This is a Phase 1, multi-centered, open-labeled, dose escalation study to evaluate the safety and preliminary efficacy of ATA3219 (as monotherapy) in participants with LN following LD (Cohort LN) and in participants with extrarenal SLE (ERL) without LD (Cohort ERL). This study is planned to be conducted in the United States, Canada, and Australia. For each cohort, up to 3 dose levels (DLs) will be explored in the dose escalation portion of the study and if needed a lower dose may be explored. Prior to undergoing any screening procedure, prospective participants must undergo the ATA3219 inventory check assessments to ensure availability of an appropriate partially human leukocyte antigen (HLA)-matched ATA3219 product lot. Before administration of ATA3219, participants will receive LD treatment (Cohort LN) or methylprednisolone treatment (Cohort ERL). For all enrolled participants, hospitalization during and following ATA3219 dosing is mandatory. Participants will receive a single dose intravenous (IV) infusion of ATA3219 (monotherapy) on Day 1. Participants will remain inpatient for a minimum of 1 week post ATA3219 dosing, where they will be frequently monitored. Clinical responses will be assessed by the investigator on Day 28 (+ 5 days) following each dose of ATA3219. For each cohort, during dose escalation, up to 3 DLs of ATA3219 are planned to be evaluated sequentially and a lower dose may be added. At least 3 and up to 6 dose-limiting toxicity (DLT)-evaluable participants, those who complete the 28-day DLT observation period, will be assessed at each DL. Within each DL, treatment will be staggered to allow appropriate safety monitoring by an independent Data Safety Monitoring Committee (DSMC).

Enrolled participants who do not receive ATA3219 for any cause (e.g., rapid deterioration) will be replaced. Participants who experience an adverse event (AE) during the 28-day DLT observation and complete the observation period will not be replaced. In addition, if a participant is treated with ATA3219 and discontinues for any reason other than due to a DLT prior to completing the 28-day DLT observation period, an additional participant may be enrolled at the dose level to ensure that the recommended phase 2 dose (RP2D) can be determined, with a goal not to exceed 6 participants treated/dose level. In rare situations, retreatment of participants with inadequate renal response may be considered.

After treatment is completed or discontinued, participants will be followed for safety and clinical response for up to 24 months from the last dose of ATA3219. A separate long-term follow-up study will be conducted to follow participants for up to a total of 15 years after their last dose of ATA3219.
FIELD: pharmaceutical industry. SUBSTANCE: fatty base has the following components, wt. -%: sunflower oil 80-65; swine fat 10-20, and beta-carotene 10-15. New bioactive fatty base is maximally similar with human fatty tissue by its physico-chemical parameters. Fatty base does not cause allergic reactions and exhibits independent curative action. EFFECT: enhanced quality of base.
Systematic, diagnostic studies applying DCE-MRI have never been performed in patients with fibromyalgia. However, characteristic contrast-enhancement patterns different from those seen in patients with rheumatoid arthritis and psoriatic arthritis have been observed in a small sample of fibromyalgia patients referred for DCE-MRI of the hands for differential diagnostic purposes at department of radiology, Frederiksberg Hospital. In these patients enhancement parameters indicative of vasodilatation and diffuse hyperperfusion involving subcutaneous tissues and muscles of the hands and fingers were found, whereas no synovial inflammation in joints or tendons could be demonstrated in the majority of these patients. Whether these observations are part of a "normal" physiological perfusion in healthy individual or a potential novel marker of disease activity remains to be studied.

If a pathological imaging pattern indicative of superficial soft tissue or muscle inflammation/hyper perfusion can be demonstrated it will have far-reaching implications for future research related to this patient population. Not only may this line of research contribute to a better neurobiological understanding of fibromyalgia and the neurobiological link between inflammation and pain modulation, but also to the development of more objective examination methods, which will make diagnosing more reliable and less subjective. Further, a better understanding of the neurobiology and phenomenological manifestations of fibromyalgia may have critical treatment implications
The function of miRNAs in intestinal inflammatory injury regulation has been studied extensively. However, the targeted delivery of these functional nucleic acid molecules to specific organs through encapsulation carriers and exerting their functional effects remain critical challenges for further research. Here, we constructed miR-146a-5p overexpression plasmid and validated the anti-inflammatory properties in the cell model. Then, the plasmid was encapsulated by the Pickering double emulsion system to investigate the role of Pickering double emulsion system in LPS-induced acute intestinal inflammatory injury. The results showed that the Pickering double emulsion system could effectively protect the integrity of plasmids in the intestinal tract, alleviate intestinal inflammatory injury, and upregulate the relative abundance of Lactobacillus reuteri. Mechanically, in vivo and in vitro experiments have shown that miR-146a-5p inhibits TLR4/NF-κB pathway to alleviate intestinal inflammation. In addition, miR-146a-5p can also regulate intestinal homeostasis by targeting the RNA polymerase sigma factor RpoD and α-galactosidase A, thereby affecting the growth of Lactobacillus reuteri. Above all, this study reveals a potential mechanism for miR-146a-5p to treat intestinal inflammation and provides a new delivery strategy for miRNAs to regulate intestinal homeostasis.
Use of ZONEGRAN was frequently associated with central nervous system-related adverse events. The most significant of these can be classified into three general categories: 1) psychiatric symptoms, including depression and psychosis, 2) psychomotor slowing, difficulty with concentration, and speech or language problems, in particular, word-finding difficulties, and 3) somnolence or fatigue.

In placebo-controlled trials, 2.2% of patients discontinued ZONEGRAN or were hospitalized for depression compared to 0.4% of placebo patients. Among all epilepsy patients treated with ZONEGRAN, 1.4% were discontinued and 1.0% were hospitalized because of reported depression or suicide attempts. In placebo-controlled trials, 2.2% of patients discontinued ZONEGRAN or were hospitalized due to psychosis or psychosis-related symptoms compared to none of the placebo patients. Among all epilepsy patients treated with ZONEGRAN, 0.9% were discontinued and 1.4% were hospitalized because of reported psychosis or related symptoms.

Psychomotor slowing and difficulty with concentration occurred in the first month of treatment and were associated with doses above 300 mg/day. Speech and language problems tended to occur after 6–10 weeks of treatment and at doses above 300 mg/day. Although in most cases these events were of mild to moderate severity, they at times led to withdrawal from treatment.

Somnolence and fatigue were frequently reported CNS adverse events during clinical trials with ZONEGRAN. Although in most cases these events were of mild to moderate severity, they led to withdrawal from treatment in 0.2% of the patients enrolled in controlled trials. Somnolence and fatigue tended to occur within the first month of treatment. Somnolence and fatigue occurred most frequently at doses of 300–500 mg/day. Patients should be cautioned about this possibility and special care should be taken by patients if they drive, operate machinery, or perform any hazardous task.
Any gender, aged 65 years and over. No known renal disease and eGFR 60ml/min or greater. Not immunosuppressed. To receive both seasonal influenza and pneumococcal polysaccharide vaccines as part of recommended clinical care.
Psoriasis biological treatment. Anti-Tnf and anti-il12/23.
A multimodal antiviral compound is described,it is effective against a wide range of respiratory viruses that invade the upper airway. The compound is supplied as a nasal spray, nasopharyngeal oral spray and a modified structure of the compound as oral medicine. Application of both nasal and nasopharyngeal spray will inhibit the virus and limit its spread; in the meantime, the oral food supplement works as a systemic antivirus and increases the immunity. The compound for spray is composed of Povidone Iodine, Glycyrrhizic acid, Deglycyrrhizinated licorice extract, black seed extract and diluted clover honey. The food supplement is comprised ofammonium glycyrrhizate, black seed extract in a diluted cloverhoney. Combining multiple effective antiviral compounds working both topically and systemically provide a multimodal new insight for protection and early treatment of Corona, influenza and other respiratory tract viruses.
The invention discloses external medicinal liquid for treating vitiligo. The external medicinal liquid is prepared from the following components in weight proportion: 20 to 40g of lead monoxide, 10 to 20g of realgar, 5 to 15g of calomel, 10 to 20g of sulfur, and 10 to 20g of sophora flavescens. The external medicinal liquid is prepared by the following steps: grinding lead monoxide, realgar, calomel and sulfur into fine powder; immersing the mixture and the sophora flavescens in a certain amount of mature vinegar for 7 days; uniformly shaking; and extracting the liquid, bottling and sealing. When the external medicinal liquid is used, the medicinal bottle is uniformly shaken, and the medicinal liquid is applied to an affected part 2-3 times a day. One month of application is taken as a course of treatment, and vitiligo can be cured after 2 to 3 courses of treatment generally. The external medicinal liquid disclosed by the invention can activate blood circulation to remove meridian obstruction, and dispel wind and remove vitiligo, and has good treatment effect and no side effect.
The subject will receive f 0.5 mL each Lymphoseek into the uterine cervix prior to surgery and subsequent SPECT/CT imaging preoperatively. Intraoperatively, following anesthesia induction, Indocyanine Green (0.5 mL) will be injected into the uterine cervix. Using near-infrared imaging, efferent lymphatic vessels and lymph nodes will be visualized and confirmed by detected radioactivity using a laparoscopic gamma counter. The preoperatively obtained SPECT/CT images will help guide the surgery.
The proposed research will (1) examine the epidemiology and health impacts of recurrent suicidal ideation on mothers over time, (2) characterize key features of suicidal ideation and finalize intervention package components within the study context, and (3) conduct a pilot clinical trial to assess the feasibility and acceptability of implementing a Suicide Prevention Package (SuPP) within an existing task-shifted depression intervention in rural Pakistan. This pilot research lays the groundwork for a future project to scale a package for multi-level suicide prevention strategies that can be integrated into community based mental health programs, particularly targeting individuals living in low-resourced settings. As the model is designed to be easily adapted and integrated, we anticipate the findings will be valuable for all researchers looking to improve population health and mental health services in disadvantaged settings. The focus of this registration is the pilot clinical trial.

A stratified cluster randomized controlled trial design, with 6 village clusters allocated in a 1:1 ratio to the intervention and control arms will be used. The stratification will be level of the Union Council (which is the smallest district administrative unit) and include Sihala and Shah Allah Ditta. While a village cluster (VC) will be the unit of randomization. Each VC will have 900-1400 population of women of reproductive age based within two to three contiguous catchment areas of the government employed community health workers called Lady Health Workers (LHWs). The reason for choosing village cluster as the unit of randomization is to minimize contamination/spillage between trial participants as the intervention will be delivered within community-based households. The intervention (KPZ) and control (EUC) village clusters will be geographically separated and the chance of intervention cluster participants regularly meeting control cluster participants will be negligible.
This invention deals with an enhanced medical treatment system which seeks input from the patient and the physician about the medical problems faced by the patient. It analyzes this information and seeks to guide physicians to a correct diagnosis of the complaint. It also seeks to educate the patient about his/her medical problems and provides information about the problem. It is able to store all this information, so that a continues record of the patient's visits and problems is kept on file and the physician is able to utilize the medical history to solve the patient's current problems. With this system in place the medical establishment will be able to improve health care delivery to the patients and be able to better manage the process of the providing health care. Furthermore, this system will also lower the cost of providing health care without compromising on the quality of health care.
The present invention relates to a method for treating breast cancer by decreasing the expression of ANT2 (adenine nucleotide translocator 2) mRNA. Particularly, the present invention provides a composition for the treatment of breast cancer, comprising ANT2 siRNA or ANT2 shRNA as an active ingredient, characterized by ability to suppress metastasis of breast cancer cells. The present composition enhances an effect of TRAIL (TNF-related apoptosis-inducing ligand) for treating the breast cancer. Also, the present invention provides a composition for treating stem cells of breast cancer, comprising ANT2 (adenine nucleotide translocator 2) siRNA or ANT2 shRNA as an active ingredient. Therefore, the present invention provides a therapeutic for breast cancer, which is highly effective for suppressing the metastasis of breast cancer cells and overcoming drug resistance. Furthermore, the therapeutic is applicable to the prevention of stem cells of breast cancer.
FIELD: medicine. ^ SUBSTANCE: what is described is a method for malignant cell elimination with the use of an effective amount of an immunotoxin with a common structure, containing a core unit of gelonin toxin and a one-chained antibody specifically targeted on a malignant cell. According to the invention, the immunotoxin can be an ingredient of a pharmaceutically acceptable composition. The immunotoxin can be delivered to the malignant cell by introduction into a cell of an immunotoxin-expressing construct which is a viral vector. ^ EFFECT: immunotoxins according to the invention exhibit lower antigenic specificity with preserved biological activity, therefore the method and the composition used in the method have substantial positive properties for a subject requiring such method. ^ 12 cl, 11 dwg, 9 tbl, 6 ex
VHL syndrome is a rare hereditary tumor syndrome caused by mutation of tumor suppressor gene VHL. One of the most important clinical manifestations and main cause of death is VHL-related renal cell carcinoma (RCC). Previous small sample studies have confirmed that the natural course of VHL-related RCC is different from that of sporadic RCC. Facing the challenges of multilesion of both kidneys, slow progress and life-long repeated surgeries in VHL-related RCC, individualized prediction of the best surgical treatment time and reduction of times of surgeries are very important to improve the prognosis of patients with VHL-related RCC. Therefore, there is an urgent need to establish a more effective and accurate prediction model for the natural course of VHL syndrome. Based on the previous establishment of the largest biobank of VHL syndrome in Asia, as well as the unique characteristics and genotype-phenotypic relationship of patients in Chinese population, this cohort-study aims to retrospectively and prospectively analyze the factors related to the natural course of VHL-related RCC. At the same time, some patients were selected for prospectively continuous molecular evolution dynamic monitoring after comprehensively considering the results of single cell sequencing, whole genome and metabonomic sequencing. This study will systematically analyze the specific molecular characteristic and evolution of VHL-related different from sporadic RCC, reveal new specific driving genes and their molecular regulatory mechanisms, and establish a multi-dimensional prediction model of natural course of VHL-related RCC based on accurate genotyping. It will provide scientific basis for accurate diagnosis and treatment of natural course of VHL-related RCC.
50% Dextrose Injection is hypertonic and may cause phlebitis and thrombosis at the site of injection. Significant hyperglycemia and possible hyperosmolar syndrome may result from too rapid administration. The physician should be aware of the symptoms of hyperosmolar syndrome, such as mental confusion and loss of consciousness, especially in patients with chronic uremia and those with known carbohydrate intolerance. The intravenous administration of this solution can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. Additives may be incompatible. Consult with pharmacist if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.  
For peripheral vein administration:  
The solution should be given slowly, preferably through a small bore needle into a large vein, to minimize venous irritation.  
For central venous administration:  
Concentrated dextrose should be administered via central vein only after suitable dilution.
PURPOSE: A composition containing an Eugenia caryophyllata Thunb. extract is provided which exhibits steroid human estrogen receptor-binding activity such as estrogen or androgen as an effective component. Because the composition has the same effect as administration of estrogen, it can be used as a prophylactic and therapeutic agent for osteoporosis or prostate cancer. CONSTITUTION: The pharmaceutical composition containing 0.1 to 50% by weight of an Eugenia caryophyllata Thunb. extract is administered through an oral, transdermal, subcutaneous, intravenous or muscular pathway and the effective amount of the extract for treatment of hormone replacement therapy is in the range of 0.001 to 100mg/kg per a day. Eugenia caryophyllata Thunb. is extracted 1 to 20 times with water or 5 to 20 times with low alcohol, filtered or centrifuged and then concentrated.
The present invention relates to a raditional Chinese medicine preparation for treating postpartum spontaneous sweating, which takes more than 10 traditional Chinese medicines of ephedra root, roasted liquoric root, Chinese magnoliavine fruit, spina date seed etc. as the raw materials. The invention has the effects of benefiting qi, nourishing yin and consolidating exterior for arresting sweating. Based on the differential treatment of the traditional Chinese medicine, the invention is developed by combining the latest scientific research results with the traditional Chinese medicine. The present invention aims at providing the traditional Chinese medicine preparation to treat postpartum spontaneous sweating. The present invention is characterized by accurate efficacy, safety, convenience, no toxicity or side effects and low price.
The patient is anesthetized and placed in a lithotomy position, after preparing and washing the vagina with normal saline, under transvaginal ultrasound guidance (Aloka-40000 vaginal probe, Japan) using needle puncture (Reproline medical Gmbh, Rheinbach/Germany). The injection of 2 ml of extracellular vesicles derived from MSCs (equivalent to 30 million cells) will be performed into one ovary of the patient (the accessible ovary).
Limb-girdle muscular dystrophies (LGMD) are muscular dystrophies that affect skeletal muscles, mostly proximal (hips and shoulder muscles). They are caused by a mutation in a gene encoding a protein, which is specific to each subtype. LGMD inheritance is either autosomal dominant or recessive. Several types of LGMD were described depending on the causative mutations (1). LGMD is one of inherited myopathies that characterized by selective involvement of muscles. Selectivity is a sign of muscle diseases and helps direct the diagnosis; however, it cannot always be identified clinically; consequently, the importance of using muscle MRI and ultrasound are to detect this selectivity and aid in the diagnosis (2). Ultrasound with a high resolution enables viewing of the muscle, nerve, and nearby structures and can provide real-time information in neuromuscular illnesses (3). Muscle Ultrasound (MUS) can detect the same patterns of muscle affection as MRI (4). In addition, it is safe, accessible, low-cost, and free of ionizing radiation, with no known contraindications and no difficulties associated with MRI, such as claustrophobia, metallic implants, and the requirement for sedation in children; hence, it can be used as a supplemental technique to electro- diagnosis (5). Ultrasound can provide real-time information related to muscle activation and movement patterns; so, selective substitution of muscle ultrasound for MRI can result in significant cost-saving for the health care system (6). However, its primary drawback is that it is operator-dependent and has a limited ability to image deeper structures (7). According to studies, MUS can provide a key provisional probable diagnosis, especially when genetic diagnosis is not accessible or expensive, or to provide guide to the proper genetic testing when it is available (2, 8). In limb girdle pattern of weakness patients, MUS assisted diagnose quadriceps sparing myopathy, selective affection of one head of gastrocnemius as medial head and soleus more than lateral head in FKRP (LGMD2I) and calpain-3 deficiency (LGMD2A), and selective affection of lateral head as in LGMD2B.

(dysferlin) (9). MUS can also help diagnose the treatable types of limb girdle myopathies like POPME by recognizing specific muscle involvement patterns (2). Few research (10), utilized the MUS to detect suspected LGMD, and none compared the MUS findings with those of the different psychometric measures. The present study aims to we aimed to evaluate the role of MUS in the assessment of patients with suspected LGMD to identify characteristic patterns these of muscle involvement in suspected cases of LGMD and to correlate changes with findings of the different psychometric scales.